SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

SynAct Pharma CEO Acquires 20,313 Shares

CEO Jeppe Øvlesen acquired 20,313 SynAct Pharma shares on Nasdaq Stockholm. The release gives no transaction value.

SYNACT

CEO Jeppe Øvlesen acquired 20,313 SynAct Pharma shares on Nasdaq Stockholm. The release provides no transaction value or prior-period comparison.Material DetailsContext by AI AnalystThis is an insider purchase disclosure at a clinical-stage biotechnology company, rather than a new operating or clin…

Related stories